<DOC>
	<DOC>NCT01759511</DOC>
	<brief_summary>The primary objective of this study is to evaluate the long term safety and tolerability of simtuzumab (GS-6624) in participants with idiopathic pulmonary fibrosis (IPF) who had previously participated in Gilead clinical trial AB0024-201.</brief_summary>
	<brief_title>Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Key Previous participation in Phase 1 Gilead clinical trial Diagnosis of idiopathic pulmonary fibrosis Females of childbearing potential and nonvasectomized males must agree to use highly effective methods of contraception Females must discontinue nursing Comply with study requirements Have adequate organ function Key History or evidence of clinically significant disorder, condition or disease that would pose a risk or interfere with the study Pregnant or lactating Clinically significant heart, hepatic or renal disease History of cancer within 5 years of screening Infection that is not controlled despite antibiotics or other treatment History of bleeding diathesis within the last 6 months of Day 1 Known history of human immunodeficiency virus, hepatitis B or C Concern's for subjects compliance Other conditions that might put the subject at high risk for treatment complications or reduce the chance to obtain data required Placed on a lung transplant list Previous participation in an idiopathic pulmonary fibrosis clinical trial other than for simtuzumab Note: Other protocol defined Inclusion/Exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Idiopathic</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>IPF</keyword>
</DOC>